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Abstract
Objective
To evaluate the safety and efficacy of cholecalciferol in patients with relapsing-remitting MS
(RRMS).
Methods
In this double-blind, placebo-controlled parallel-group, 2-year study, 181 patients with RRMS
were randomized 1:1. Key inclusion criteria were a low serum 25-hydroxy vitamin D (25OHD)
concentration (<75 nmol/L), a treatment with interferon beta-1a 44 μg (SC 3 times per week)
4 months ± 2 months before randomization, and at least one documented relapse during the
previous 2 years. Patients received high-dose oral cholecalciferol 100,000 IU or placebo every
other week for 96 weeks. Primary outcome measure was the change in the annualized relapse
rate (ARR) at 96 weeks. Secondary objectives included safety and tolerability of cholecalciferol
and efficacy assessments (ARR, MRI parameters, and Expanded Disability Status Scale
[EDSS]).
Results
The primary end point was not met. In patients who completed the 2-year follow-up (45 with
cholecalciferol and 45 with placebo), all efficacy parameters favored cholecalciferol with an
ARR reduction (p = 0.012), less new hypointense T1-weighted lesions (p = 0.025), a lower
volume of hypointense T1-weighted lesions (p = 0.031), and a lower progression of EDSS (p =
0.026). The overall rate of adverse events was well balanced between groups.
Conclusions
Although the primary end point was not met, these data suggest a potential treatment effect of
cholecalciferol in patients with RRMS already treated with interferon beta-1a and low serum
25OHD concentration. Together with the good safety profile, these data support the explo-
ration of cholecalciferol treatment in such patients with RRMS.
Clinicaltrials.gov identifier
NCT01198132.
Classification of evidence
This study provides Class II evidence that for patients with RRMS and low serum 25OHD,
cholecalciferol did not significantly affect ARRs.
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Optimizing treatment in relapsing-remitting MS (RRMS) is
an unmet need. Immunomodulators or immunosuppressants
are efficient to lower relapse rate, but they are not deprived of
adverse effects, and poor response to treatment is still
a concern.1,2
Vitamin D (VD) is a biological regulator of the immune
system.3 VD deficiency is a risk factor for MS, and the risk of
relapse and the risk of having new MRI lesions are inversely
correlated with 25-hydroxy vitamin D (25OHD) blood levels,
both in adults and children.4–8 VD is safe even at very high
doses in RRMS.9 Double-blind, placebo-controlled trials gave
controversial results and were characterized by a methodo-
logical heterogeneity.10,11 All studies with cholecalciferol, but
one, gave positive results on biological parameters of in-
flammation, on MRI parameters of MS activity, or on quality
of life.12–15 However, none of these studies showed a clinical
benefit with VD treatment. The present study assessed the
safety and efficacy of cholecalciferol in patients with RRMS,
already treated with interferon beta-1a 44 μg subcutaneously 3
times per week (SCTIW), using 2 original parameters at in-
clusion, clinically active RRMS and VD insufficiency, com-
bined with a 2-year duration.
Methods
Primary research question
This phase 2, multicenter, randomized, double-blind,
placebo-controlled parallel-group study was designed
to evaluate the efficacy of cholecalciferol (Crinex labora-
tories, Montrouge, France) in patients with RRMS that
was conducted from January 2010 to June 2013 at 27 sites
in France. Class II evidence is provided here as more
than 20% of randomized patients did not complete the
study.
Standard protocol approvals, registrations,
and participant consents
Before initiating the study, the study protocol was approved
by a national review board, the CPP Sud-Me´diterrane´e IV
ethics committee. Written informed consent was obtained
from all the study participants before any study-related pro-
cedures were performed (ClinicalTrials.gov identifier
NCT01198132). The study was conducted in accordance
with the International Conference on Harmonization
Guidelines for Good Clinical Practice and the Declaration of
Helsinki.
Patients
Eligible patients were aged between 18 and 65 years, with
a diagnosis of RRMS based on the 2005 revised McDonald
criteria,16 low serum 25OHD concentration (VDC, < 75
nmol/L), a treatment with interferon beta-1a 44 μg (or
22 μg in case of intolerance to 44 μg) SCTIW for 4 months
± 2 months at the randomization visit, and an Expanded
Disability Status Scale (EDSS) score from 0 to 5.0, with at
least one documented relapse during the previous 2 years
and stable disease (no episode) over the last 30 days. Main
exclusion criteria were use of drugs affecting VD metabo-
lism other than corticosteroids; previous or ongoing hy-
percalcemia; and abnormal renal function defined by
eGFR < 60 mL/min. Eligible patients were identified in the
clinic at each study site and recruited according to the
protocol.
Study design and treatment
After enrollment, randomization was performed within an
8-week period, and patients were randomly assigned (1:1) to
receive cholecalciferol or placebo at the second study visit.
The composition, appearance, and packaging of placebo
treatment were identical to those of active treatment. When
starting medication, each subject was assigned a randomiza-
tion number according to a chronological sequential order per
site. A unique randomization number was assigned to each
subject at the initial visit. This number was retained by the
subject until the completion of the study. Treatment kits were
labeled with batch number, expiry date, randomization
number, storage/administration conditions, and a kit identi-
fication number.
Randomized patients were treated for 96 weeks. Treatment
was an oral solution packaged in 2 mL yellow glass (type III)
ampoules with 2 self-breakable tips, containing 2.5 mg of
cholecalciferol corresponding to 100,000 IU or placebo.
Concomitant medications included medications that had
started before the first dose of cholecalciferol or placebo and
continued after the first dose of blinded treatment. Study visits
were V1 (screening, week W-8), V2 (baseline, W0), V3
(W24), V4 (W48), V5 (W72), and V6 (W96). At each visit
from V2 to V5, patients received a kit to self-administering
orally an ampoule every other week (equivalent to a daily dose
of 7,143 IU of cholecalciferol) during the 96-week treatment
period. Clinical (EDSS and Paced Auditory Serial Addition
Task 3, second version [PASAT-3]) and quality of life (EQ-
5D-3L) assessments were performed at all study visits since
Glossary
25OHD = 25-hydroxy vitamin D; ARR = annualized relapse rate; BOCF = Baseline Observed Carried Forward; DRAE =
disease-related adverse event; EDSS = Expanded Disability Status Scale;HR = hazard ratio; ITT = intention to treat; NEDA =
No Evidence of Disease Activity; PASAT = Paced Auditory Serial Addition Task; RRMS = relapsing-remitting MS; SCTIW =
subcutaneously 3 times per week; SDRAE = serious DRAE; TEAE = treatment emergent adverse event; VD = vitamin D;
VDCM = mean of VDC.
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baseline. MRI scans were performed at baseline and V6 and
were analyzed at a central MRI center by trained staffmasked
to study group assignment. Screening and baseline routine
laboratory tests including blood 25OHD, renal function, and
calcium levels were performed to comply with inclusion and
exclusion criteria and repeated each month during the first 6
months and then quarterly to ensure safety.
Outcomes
The primary objective was the reduction of the annualized
relapse rate (ARR), defined as the ratio of the number of
relapses under treatment by the exposure duration, in years.
Key secondary objectives were time to first relapse; EDSS
progression; MRI parameters (number of new or enlarged
T1-and T2-weighted lesions, T2-weighted MRI lesion load,
number of T1-weighted Gd-enhancing lesions, volume
change of hypointense T1-weighted MRI lesions, total brain
volume, and brain gray and white matter volume); change in
cognitive abilities; and change in quality of life and treatment
safety.
Safety monitoring
Safety was assessed from reports of adverse events, serious
adverse events, disease-related adverse events (DRAEs),
routine laboratory tests, and vital signs. DRAEs were coded
according to the Medical Dictionary for Regulatory Activities
coding system. Values for clinical laboratory assessments were
compared with both the appropriate normal ranges and
ranges of potential clinical concern. Any abnormal test result
or other safety assessment judged by the investigator to be
clinically significant was recorded as an adverse event or
a serious adverse event.
Population and statistical analysis
The Full Analysis Set was constituted by all the randomized
patients (intention to treat [ITT] population). Supportive and
post hoc analyses were conducted on the ITT set, after ex-
clusion of subjects with major deviations, and a completers’
population, which corresponded to the group of patients who
completed the 96-week trial, as only those patients underwent
EDSS and MRI examination at the final visit after 2 years (V6).
The primary efficacy analysis compared the cholecalciferol
group with placebo using a generalized linear model fea-
turing a Poisson regression adjusted for baseline values of
annualized relapse rate (ARRb), sex, age, EDSS, controlled
for overdispersion, and using the log-transformed exposure
time as an offset variable. ARR values were descriptively
reported by geometric means due to the positive skewness
of the distribution.
The trial was powered according an assumed rate ratio (rR)
between cholecalciferol and placebo of 0.75, a mean number
of 1 relapse per year, and a correlation R(ARRb, ARR) of 0.7.
Under these conditions, a sample size of 106 patients/group
was needed for a power of at least 0.75 at a 95% 2-sided
significance level.
Missing ARR data on the number of relapses after premature
interruption were imputed by baseline ARR values.
Time to first relapse was compared using Cox regression
adjusted on baseline ARR. Any dropout was considered as
failure at trial interruption time. For sensitivity purposes,
a supportive analysis was based in differentiating on drug-
related dropout considered as failure, with drug-unrelated
dropout considered as censored at dropout date, the differ-
entiation established by an adjudication committee blind to
treatment.
MRI values at V6, for the completers’ population, were
compared between treatment groups in adjusting for baseline,
sex, and age. Log transformation was used for the number of
new or enlarged T1- and T2-weighted lesions and the number
of T1-weighted Gd lesions, and the ratio Final/Baseline was
reported. Disability progression was defined as increase of at
least 1 unit from baseline EDSS. EDSS at last visit was com-
pared between the 2 groups by a linear model adjusting for
baseline.
Supportive analyses were as follows: (1) for early drug-related
dropouts (either for poor efficacy or safety), the short expo-
sure duration inducing relapse-free profile (ARR = 0) may
falsely conclude into therapy success: we corrected this bias in
evaluating a corrected ARR in assuming post-dropout period
ARR by baseline ARR following the Baseline Observed Car-
ried Forward (BOCF) principle; and (2) final EDSS, for drug-
related dropouts, was also assimilated to BOCF. Although
ARR was the main end point of this study, progression of the
disease now constitutes a primary concern for regulatory
authorities. Therapy success may thus be considered on both
end points: a patient characterized by relapse-free follow-up
and without EDSS progression (EDSSb ≥ EDSSF). Response
rate was compared between the 2 treatment groups in
adjusting for baseline EDSS and ARRb. A response based on
MRI was also defined in considering therapy success when
radiologic disease-free status was observed (i.e., no Gd-
enhancing lesions and no new or enlarging T2-weighted
lesions on brain MRI). A last alternative combining the 2 first
response definitions is the recently proposed No Evidence of
Disease Activity (NEDA-3) binary end point defined as no
relapses + no sustained disability progression + radiologic
disease-free status.17
The effect of serum 25OHD concentration (VDC), measured
at each visit, was also assessed. The summary mean of VDC
(VDCM) was calculated during the follow-up period (V3 to
V6). Poisson regression and linear model tested the VDCM
effect on relapse count and EDSS, in adjusting for baseline
values. The PASAT-3 and the EQ-5D-3L scores were com-
pared between treatment groups using analysis of covariance
adjusting for baseline value.
The safety analysis was performed on all randomized
patients who received at least 1 dose of study drug during
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the study. The number of treatment emergent adverse
events (TEAEs) of any type and the total number of sub-
jects with at least one TEAE were compared between
treatment groups. The same analysis was performed in
comparing suspected DRAEs, serious DRAEs (SDRAEs),
and deaths.
The study was analyzed in compliance with standard Good
Clinical Practice regulations, database, and statistical analysis
plan locked before unblinding. Software package SAS, version
9.4 (SAS Institute Inc) and R version 3.3.2 were used for
analysis.
Data availability
We provide qualified researchers access to individual patient-
level data through the Merck KGaA’s data-sharing portal:
merckgroup.com/en/research/our-approach-to-research-
and-development/healthcare/clinical-trials/commitment-re-
sponsible-data-sharing.html.
Results
Study population
Between January 2010 and June 2013, a total of 181 patients
were screened, and 129 were randomized, constituting the
ITT population (figure). Themost common reason for failure
to be randomized was a normal blood 25OHD level. De-
mographics and baseline characteristics of ITT population are
shown in table 1. A total of 39 dropouts were recorded during
the 2-year follow-up. Most reasons of dropout were related to
the treatment of RRMS with either a lack of efficacy (relapse)
or to patient willing or physician deciding to switch to another
disease-modifying drug. A total of 90 patients (45 in each
treated group) completed the trial, constituting the com-
pleters’ population.
Efficacy
A total of 85 patients (65.8%) were relapse-free, and the
highest value of ARR = 1.5 was observed for 2 patients.
Mean ARR in the cholecalciferol group was 0.094 compared
with 0.110 for placebo; this difference was not statistically
significant (ITT sample: rR = 0.799, 95% CI 0.481–1.32, p =
0.38, Poisson regression). Conversely, ARR was signifi-
cantly lower on the completers’ population: rR = 0.395,
95% CI 0.186–0.012, p = 0.01. A total of 19 relapses oc-
curred in the cholecalciferol group compared with 25 with
placebo. Time to first relapse was not significantly different
between the 2 groups (hazard ratio [HR] = 0.801; 95% CI
0.403–1.454; p = 0.43).
For completers, at baseline, MRI measurements were in
accordance with the protocol for 49 patients in the chole-
calciferol group and for 47 patients in the placebo group,
and final values at last visit were available for 44 and 41 of
them. A significant mean reduction of new T1 lesions (rate
ratio rR = 0.494, 95% CI 0.267–0.913; p = 0.03) and a de-
crease in the volume of hypointense T1-weighted MRI
lesions (−312 mm3, 95% CI −596 to −29; p = 0.03) were
recorded in the cholecalciferol group vs placebo. There
were no significant changes in either of the other MRI
parameters studied (number of Gd-enhancing T1 and new
T2 lesions, as well as brain, T2 lesions, and gray matter and
Figure Trial flowchart
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white matter volumes). Average progression of the EDSS
score was significantly lower in the cholecalciferol group
(−0.06 ± 0.78) compared with the placebo group (0.32 ±
0.87, 95% CI −0.614 to −0.043; p = 0.03). There was no
difference in change of quality of life measured by the EQ-
5D-3L or the PASAT-3 total score between the 2 experi-
mental groups.
VDC at baseline was similar between treatment groups,
whereas cholecalciferol administration roughly tripled, at V6,
mean VDC compared with the placebo group: 156.92 mmol/
L vs 57.23 mmol/L, p < 0.001. VDC showed a significant
reduction effect on ARR (rR = 0.995 per nmol/L [95% CI
0.990–0.999], p = 0.04) and on EDSS progression with
a mean decrease of EDSS of −0.003 per 1 nmol/L increase of
VDC (95% CI −0.006 to −0.001; p = 0.006).
Post hoc analysis
There were 39 dropouts, almost 3 times higher than ini-
tially estimated. Drug-related dropouts were the most
frequent cause. The corrected ARRc, used to avoid the
potential bias of early dropout on ARR estimate, was sig-
nificantly lower in the cholecalciferol group both in the
ITT (rR = 0.502, 95% CI 0.326–0.764; p = 0.001) and in
the completers’ population (rR = 0.395, 95% CI
0.186–0.801; p = 0.01). When dropouts were considered as
relapse, the observed effect of the cholecalciferol treatment
was significant (HR = 0.508, 95% CI 0.286–0.901; p =
0.02). When considering drug-related dropout as a failure,
66% fewer relapses were found in the cholecalciferol group
compared with placebo (HR = 0.333, 95% CI 0.164–0.675;
p = 0.002). The proportion of relapse-free patients at last
visit (V6) was not significantly higher in the cholecalciferol
group (69.8%) vs placebo (62.1%, OR = 1.70, 95% CI
0.77–3.76; p = 0.19). When considering the ITT pop-
ulation and assimilating drug-related dropouts as re-
lapsing, these proportions became 65.1% and 45.5% and
were significantly different (OR = 3.22, 95% CI 1.45–7.19;
p = 0.004). Similarly, in the completers’ population, these
proportions of relapse-free patients between cholecalcif-
erol and placebo groups were significantly different (75.6%
and 60%, respectively, OR = 3.24, 95% CI 1.14–9.22; p =
0.03). A bias being possible in case of an unbalance be-
tween completers and noncompleters, baseline de-
mographics were compared between these 2 groups with
the same set of parameters as for the ITT population in
table 1. There was a female predominance in the non-
completers group, 82.1%, compared with completers,
63.3% (p = 0.03). No statistical difference could be noted
between the 2 groups for any of the other demographic
parameters.
When responders were defined by the absence of relapse
(ARR = 0) and progression (EDSSf-EDSSb ≤ 1), 49.2% and
31.2% responders were found in the cholecalciferol group
and the placebo group (OR = 2.18, 95% CI 1.05–4.53; p =
0.04). Similarly, the radiologic disease-free status was also
in favor of the cholecalciferol treatment (OR = 2.172, 95%
CI 1.016–4.640; p = 0.045). The NEDA-3 binary end point
was met by 22.1% patients in the cholecalciferol group
compared with 9.1% with placebo (OR = 3.44, 95% CI =
1.14–10.33; p = 0.03).
Table 1 Patient characteristics
Baseline characteristics
Mean
Placebo
(n = 66)
Cholecalciferol
(n = 63) p Value
Age (SD), y 36.73 (8.37) 38.40 (9.31) 0.29
Sex, female, n (%) 39 (59.1) 50 (79.4) 0.01
Height (SD), m 1.71 (0.08) 1.67 (0.09) 0.009
Weight (SD), kg 70.84 (13.28) 68.29 (13.12) 0.28
BMI (SD), kg/m2 24.12 (3.72) 24.41 (3.99) 0.67
No. of relapses since disease onset (SD) 2.74 (1.62) 2.89 (2.26) 0.68
No. of relapses in the last 2 y (SD) 1.82 (0.98) 1.94 (1.52) 0.61
Disease duration (SD), y 5.59 (4.83) 5.13 (5.33) 0.61
Time since diagnosis (SD), y 2.21 (2.45) 3.00 (4.48) 0.21
EDSS score at baseline (SD) 1.22 (1.16) 1.66 (1.43) 0.05
EQ-5D-3L score at baseline (SD) 1.32 (0.29) 1.34 (0.32) 0.67
25OHD serum concentration (SD), nmol/L 48.25 (16.22) 49.19 (17.54) 0.76
Abbreviations: BMI = body mass index; EDSS = Expanded Disability Status Scale.
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Safety
A total of 126 subjects (61 cholecalciferol, 65 placebo) were
known to have been treated at least once during this study
either by cholecalciferol or placebo (table 2). No patient
died during the study. At least one TEAE was recorded in 78
subjects (61.9%): 43 in the cholecalciferol group (70.5%)
and 35 in the placebo group (53.8%). Serious TEAEs were
noted in 16.7% of the patients: 15.4% in the cholecalciferol
group and 18% with placebo. A total of 6 TEAEs (4.8%)
leading to treatment discontinuation were recorded: 3
(4.9%) in the cholecalciferol and 3 (4.6%) in the placebo
group. Nine subjects (7.1%) discontinued treatment because
of severe or life-threatening TEAEs: 5 patients (8.2%) in the
cholecalciferol group and 4 (6.2%) for placebo. In the VD
group, TEAEs were appendicitis, back pain, skin necrosis,
fetal death, and breast cancer. The 4 severe or life-
threatening TEAEs in the placebo group were abdominal
abscess, lung malignant neoplasm, peripheral arterial oc-
clusive disease, and nephrolithiasis. A total of 15 subjects
(11.9%) had drug-related TEAEs, and 3 others (2.4%) had
SDRAEs.
Discussion
The present study, in line with previous works, showed that
cholecalciferol at 100,000 IU every 2 weeks was well tolerated.
The study did not demonstrate a reduction of the ARR, the
primary efficacy measure, in the ITT population. However, in
the completers’ population, treatment with cholecalciferol
was associated with a lower ARR, a reduction of the number of
new T1 lesions, a lower volume of hypointense T1-weighted
MRI lesions, and with a significantly lower progression of
EDSS. Although post hoc analysis may be considered as
“hypothesis generating,” it is in accordance with previous
works showing that patients with low VDC were more likely
to have MRI lesions, worse EDSS score, and more relapses.10
Of interest, in the present study, the number of relapses,
adjusted for baseline, significantly decreased with increased
mean 25OHD concentrations, and a benefit on EDSS pro-
gression was also noted.
To date, CHOLINE is the largest 2-year randomized
controlled trial in RRMS using cholecalciferol. It was
constructed with a cautious selection of patients to prevent
some caveats from previous studies. Three selection crite-
ria, at least, seemed key ones. The first one was to recruit
clinically active RRMS patients, as ARR was the primary
endpoint. Second, cholecalciferol was started in patients
already treated with interferon beta-1a, as it has been
proposed that those 2 molecules may act either synergis-
tically or additively on blood monocytes and on MS
parameters of activity.18–21 Third, a low 25OHD blood
level was required for inclusion, a large literature showing
deleterious effects of VD deficiency on human health with
the lowest blood levels being associated with the worst
conditions.
An important limitation of this study is its statistical power.
One first reason for that was the difficulty to achieve inclusion
goal (n = 210). This was likely due to the number of other
alternatives for treating RRMS. It thus was decided to extend
the inclusion period from 2 years to 3.5 years, but only 181
patients could be screened. Second, the sample size had been
calculated on the basis of 1 relapse per year. This was an
overestimation, all the more as interferon beta-1a was
expected to reduce relapse rate. Third, dropouts, initially es-
timated at 10%, accounted in fact for 28.6% for the chole-
calciferol group and 31.8% for placebo. Although unexpected
and potentially explained by the numerous alternatives to the
interferon treatment that led patients or physicians, or both,
to discontinue the trial, we also considered this high dropout
rate as potentially meaningful all the more as demographics of
completers and noncompleters were similar. This suggests
that dropouts were not biased by a difference in disease profile
or disease severity at onset, and this was the basis for post hoc
analyses.
Although the present study did not meet the primary end
point of reducing the relapse rate in patients with RRMS,
results in the completer’s population are encouraging and
support the use of the methodological parameters defined in
this work. Further trials are warranted to refine the thera-
peutic interest of cholecalciferol in patients with RRMS.
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Table 2 Safety data
Adverse events, n (%)
Placebo
(n = 65)
Cholecalciferol
(n = 61)
p
Value
TEAEa 35 (53.8) 43 (70.5) Ns
Serious TEAE 10 (15.4) 11 (18.0) Ns
TEAE leading to treatment
discontinuation
3 (4.6) 3 (4.9) Ns
Serious TEAE leading to
treatment discontinuation
3 (4.6) 1 (1.6) Ns
Severe or life-threatening
TEAE
4 (6.2) 5 (8.2) Ns
Drug-related TEAEb 9 (13.8) 6 (9.8) Ns
Drug-related serious TEAEb 2 (3.1) 1 (1.6) Ns
Abbreviation: TEAE = treatment emergent adverse event.
a Not present before medical treatment or already present but worsens
either in intensity or frequency following the treatment.
b Considered by the investigator as at least possibly related to the studied
drug.
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